- Home
- KLTO vs SNOA Comparison
KLTO vs SNOA Comparison
Compare KLTO & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- SNOA
- Stock Information
- Founded
- KLTO 2019
- SNOA 1999
- Country
- KLTO United States
- SNOA United States
- Employees
- KLTO N/A
- SNOA N/A
- Industry
- KLTO
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- SNOA Health Care
- Exchange
- KLTO NYSE
- SNOA Nasdaq
- Market Cap
- KLTO 7.1M
- SNOA 6.4M
- IPO Year
- KLTO N/A
- SNOA 2007
- Fundamental
- Price
- KLTO $0.21
- SNOA $3.32
- Analyst Decision
- KLTO
- SNOA
- Analyst Count
- KLTO 0
- SNOA 0
- Target Price
- KLTO N/A
- SNOA N/A
- AVG Volume (30 Days)
- KLTO 35.4M
- SNOA 60.2K
- Earning Date
- KLTO 05-15-2025
- SNOA 06-16-2025
- Dividend Yield
- KLTO N/A
- SNOA N/A
- EPS Growth
- KLTO N/A
- SNOA N/A
- EPS
- KLTO N/A
- SNOA N/A
- Revenue
- KLTO N/A
- SNOA $13,973,000.00
- Revenue This Year
- KLTO N/A
- SNOA $23.89
- Revenue Next Year
- KLTO N/A
- SNOA $25.45
- P/E Ratio
- KLTO N/A
- SNOA N/A
- Revenue Growth
- KLTO N/A
- SNOA 13.51
- 52 Week Low
- KLTO $0.11
- SNOA $1.75
- 52 Week High
- KLTO $0.99
- SNOA $9.37
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- SNOA 52.15
- Support Level
- KLTO N/A
- SNOA $3.05
- Resistance Level
- KLTO N/A
- SNOA $3.60
- Average True Range (ATR)
- KLTO 0.00
- SNOA 0.19
- MACD
- KLTO 0.00
- SNOA -0.01
- Stochastic Oscillator
- KLTO 0.00
- SNOA 49.09
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.